Feng Jia-Xuan, Lu Qing-sheng, Jing Zai-Ping, Yang Yang, Nie Bing, Bao Jun-min, Zhao Zhi-qing, Feng Xiang, Hong Yi, Pei Yi-fei, Yuan Liang-xi
Department of Vascular Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Zhonghua Wai Ke Za Zhi. 2011 Oct 1;49(10):883-7.
To analyze the long-term results of fibrin glue embolization to eliminate type I endoleaks after endovascular aneurysm repair (EVAR), and to assess the feasibility and durability of this technique.
From August 2002 to June 2010, among the 953 EVAR patients, 51 (5.4%) patients underwent intraoperative transcatheter fibrin glue sac embolization to resolve type I endoleak persisting after initial intraoperative maneuvers to close the leak or in necks too short or angulated for cuff placement. Computed tomographic angiography was performed to assess the outcome after 3, 6, and 12 months and annually thereafter. A retrospective study was conducted, and characteristics of the patients, intra-sac pressure, hospital course, and long-term outcomes were recorded.
Among the 51 patients, 19 (37.3%) patients had proximal necks long < 10 mm, and 6 (11.8%) patients had proximal neck angulation > 60°; 22 patients (3 additional iliac extension, 14 cuffs, and/or 8 stents) had been placed with additional devices. After fibrin glue injection, 50 (98.0%) of the 51 endoleaks were successfully resolved, and intra-sac pressure (including systolic, diastolic, mean pressures, pulse pressure, and the mean pressure indexes) decreased significantly in these cases. The patient who failed embolotherapy was converted to open surgery (2.0%); he died 2 months later from multiorgan failure. And other two (4.8%) patients died in the peri-operative period from myocardial infarction. The median of follow-up of 48 patients was 45 months (range 4 - 106 months). The mean maximal aneurysm diameter fell from the baseline (61.5 ± 15.2) mm to (48.8 ± 10.1) mm (P = 0.000). Three (6.2%) patients died in the follow-up duration (1 aneurysm-related, died of renal failure which was caused by the compromised renal artery). Cumulative survival was 97.9% at 1 year, 94.5% at 3 years, and 90.8% at 4 years. No recurrent type I endoleak or glue-related complications were observed in follow-up.
Fibrin glue embolization to eliminate type I endoleak after EVAR has yielded promising results in this study, and it can effectively and durable resolve the type I endoleaks. Balloon occlusion of the inflow of the endoleak must be done during glue injection, to enhance the safety and facilitate formation of a structured fibrin clot.
分析纤维蛋白胶栓塞术消除血管内动脉瘤修复术(EVAR)后I型内漏的长期结果,并评估该技术的可行性和耐久性。
2002年8月至2010年6月,在953例EVAR患者中,51例(5.4%)患者在术中接受经导管纤维蛋白胶瘤腔栓塞术,以解决在初次术中操作关闭内漏后仍持续存在的I型内漏,或用于处理颈部过短或成角过大而无法放置袖带的情况。在术后3、6和12个月以及此后每年进行计算机断层血管造影以评估结果。进行了一项回顾性研究,记录患者的特征、瘤腔内压力、住院过程和长期结果。
51例患者中,19例(37.3%)近端颈部长度<10 mm,6例(11.8%)近端颈部成角>60°;22例患者(另外3例髂动脉延伸、14例袖带和/或8例支架)放置了额外的装置。注射纤维蛋白胶后,51例内漏中有50例(98.0%)成功解决,这些病例的瘤腔内压力(包括收缩压、舒张压、平均压、脉压和平均压力指数)显著降低。栓塞治疗失败的患者转为开放手术(2.0%);他在2个月后死于多器官功能衰竭。另外2例(4.8%)患者在围手术期死于心肌梗死。48例患者的中位随访时间为45个月(范围4 - 106个月)。平均最大动脉瘤直径从基线时的(61.5±15.2)mm降至(48.8±10.1)mm(P = 0.000)。3例(6.2%)患者在随访期间死亡(1例与动脉瘤相关,死于由肾动脉受损引起的肾衰竭)。1年时累积生存率为97.9%,3年时为94.5%,4年时为90.8%。随访中未观察到复发性I型内漏或与胶水相关的并发症。
本研究中,纤维蛋白胶栓塞术消除EVAR后I型内漏取得了有前景的结果,且能有效且持久地解决I型内漏。在注射胶水期间必须对内漏的流入进行球囊封堵,以提高安全性并促进形成结构化的纤维蛋白凝块。